Abstract
Endothelial progenitor cells (EPCs) are a population of bone marrow derived cells which have been attributed with the ability to migrate into areas of tissue ischemia and to posses reparative qualities. EPCs have been shown to be decreased in level and function in various inflammatory disorders. Psoriasis and psoriatic arthritis are associated with an increase in cardiovascular morbidity. The aim of the study was to investigate the number of EPCs among patients suffering from psoriasis and psoriatic arthritis. Patients suffering from active psoriasis and psoriatic arthritis were recruited as well as healthy controls. Disease activity was assessed with the DAS-28, BASDAI and PASI scores. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using the CD34/133 and CD34/KDR. No significant difference was found between numbers of EPCs between healthy controls, patients with psoriasis and psoriatic arthritis. A significant correlation was found between levels of VGEF and the BASDAI score. The results of the current study do not support a significant role for EPCs in the pathogenesis of psoriasis and psoriatic arthritis.
Similar content being viewed by others
References
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600. doi:10.1056/NEJMoa022287
George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A et al (2004) Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 25(12):1003–1008. doi:10.1016/j.ehj.2004.03.026
George J, Hertz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A et al (2003) Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 23(12):e57–e60. doi:10.1161/01.ATV.0000107029.65274.db
Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D et al (2005) Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111(2):204–211. doi:10.1161/01.CIR.0000151875.21836.AE
Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D et al (2006) Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 75(25):2364–2369. doi:10.1016/j.lfs.2006.07.035
Schon MP, Boehncke W (2005) Psoriasis. N Engl J Med 352(18):1899–1912. doi:10.1056/NEJMra041320
Goffe B (2004) Etanercept (Enbrel)—an update. Skin Therapy Lett 9(10):1–4
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Etanercept Psoriasis Study Group et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 20(349):21
Mease PJ (2005) Psoriatic arthritis therapy advances. Curr Opin Rheumatol 17(4):426–432. doi:10.1097/01.bor.0000166382.96024.85
Rosenzweig A (2003) Endothelial progenitor cells. N Engl J Med 348(7):581–582. doi:10.1056/NEJMp020175
Ingram DA, Caplice NM, Yoder MC (2005) Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 106(5):1525–1531. doi:10.1182/blood-2005-04-1509
Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18):2356–2363. doi:10.1161/01.CIR.0000164260.82417.3F
Dulic-Sills A, Blunden MJ, Mawdsley J, Bastin AJ, McAuley D, Griffiths M et al (2006) New flow cytometric technique for the evaluation of circulating endothelial progenitor cell levels in various disease groups. J Immunol Methods 316(1–2):107–115. doi:10.1016/j.jim.2006.08.011
George J, Shmilovich H, Deutsch V, Pick M, Miller H, Keren G et al (2006) Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng 12(2):331–335. doi:10.1089/ten.2006.12.331
Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25(1):60–66
Masuda J, Mitsuyama K, Yamasaki H, Takedatsu H, Okamura T, Andoh A et al (2007) Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int J Mol Med 19(2):221–228
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291
Anandarajah AP, Ritchlin CT (2004) Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 16(4):338–343. doi :10.1097/01.bor.0000129718.13939.81<
Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592. doi:10.1016/j.semarthrit.2004.07.010
Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC (2007) Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 66(7):865–870. doi:10.1136/ard.2006.065631
Fadini GP, Agostini C, Sartore S, Avogaro A (2007) Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194(1):46–54. doi:10.1016/j.atherosclerosis.2007.03.046
van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8(5):R151. doi:10.1186/ar2045
Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38(1):13–19
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172
Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y et al (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36(4):203–209. doi:10.1016/j.semarthrit.2006.09.001
Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 15(57):287–293. doi:10.1002/art.22530
Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Säemann M et al (2007) Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 66(10):1284–1288. doi:10.1136/ard.2006.066605
Shantsila E, Watson T, Tse HF, Lip GY (2007) Endothelial colony forming units: are they a reliable marker of endothelial progenitor cell numbers. Ann Med 39(6):474–479. doi:10.1080/07853890701329283
Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ablin, J.N., Goldstein, Z., Aloush, V. et al. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol Int 29, 257–262 (2009). https://doi.org/10.1007/s00296-008-0676-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-008-0676-7